{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:39:29Z","timestamp":1792751969306,"version":"4.5.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Abstract<\/jats:title><jats:p>Routine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines \u2013 bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>Human Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and relevance<\/jats:title><jats:p>As these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1386167","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:46:22Z","timestamp":1713879982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Cervical cancer prevention by vaccination: review"],"prefix":"10.3389","volume":"14","author":[{"given":"Julio Cesar","family":"Gonz\u00e1lez-Rodr\u00edguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Cruz-Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Madrid-Marina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.21149\/spm.v58i2.7780","article-title":"The burden of cancer in Mexico, 1990-2013","volume":"58","author":"G\u00f3mez-Dant\u00e9s","year":"2016","journal-title":"Salud Publica Mex"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: a synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob Heal"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2016.07.015","article-title":"Cervical cancer in Central and South America: Burden of disease and status of disease control $","volume":"44","author":"Murillo","year":"2016","journal-title":"Cancer Epidemiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-019-6388-4","article-title":"High risk HPV infection prevalence and associated cofactors: A population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program","volume":"19","author":"Torres-Poveda","year":"2019","journal-title":"BMC Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-46543-8","article-title":"The burden of 14 hr-HPV genotypes in women attending routine cervical cancer screening in 20 states of Mexico: a cross-sectional study","volume":"9","author":"Campos-Romero","year":"2019","journal-title":"Sci Rep"},{"key":"B9","first-page":"52","article-title":"Norma Oficial Mexicana NOM-014-SSA2-1994,Para la prevenci\u00f3n, detecci\u00f3n, diagn\u00f3stico, tratamiento, control y vigilancia espidemiol\u00f3gica del c\u00e1ncer cervico uterino","volume":"52","year":"2006","journal-title":"D Of La Fed"},{"key":"B10","article-title":"Prevenci\u00f3n y Control del C\u00e1ncer de la Mujer 2013 - 2018","volume":"98","year":"2018","journal-title":"D Of La Fed"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sxmr.2019.09.005","article-title":"Cervical cancer screening: past, present, and future","volume":"8","author":"Bedell","year":"2020","journal-title":"Sex Med Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw354","article-title":"Impact and effectiveness of the quadrivalent human papillomavirus vaccine: A systematic review of 10 years of real-world experience","volume":"63","author":"Garland","year":"2016","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-14-700","article-title":"Barriers and facilitators to HPV vaccination of young women in high-income countries: A qualitative systematic review and evidence synthesis","volume":"14","author":"Ferrer","year":"2014","journal-title":"BMC Public Health"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.08.020","article-title":"Understanding the public health value and defining preferred product characteristics for therapeutic human papillomavirus (HPV) vaccines: World Health Organization consultations, October 2021\u2014March 2022","volume":"40","author":"Prudden","year":"2022","journal-title":"Vaccine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"106399","DOI":"10.1016\/j.ypmed.2020.106399","article-title":"HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010\u20132019","volume":"144","author":"Bruni","year":"2021","journal-title":"Prev Med (Baltim)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800219","article-title":"A prime-pull-amplify vaccination strategy to maximize induction of circulating and genital-resident intraepithelial CD8+ Memory T cells","volume":"202","author":"\u00c7uburu","year":"2019","journal-title":"J Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000629","article-title":"Cervical cancer prevention in low- and middle-income countries","volume":"64","author":"Allanson","year":"2021","journal-title":"Clin Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100836","article-title":"Human papillomavirus vaccination uptake in low-and middle-income countries: a meta-analysis","volume":"34","author":"Dorji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.3390\/vaccines10060837","article-title":"B cell responses upon human papillomavirus (HPV) infection and vaccination","volume":"10","author":"Prabhu","year":"2022","journal-title":"Vaccines"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1517\/14728214.2012.744393","article-title":"Emerging human papillomavirus vaccines","volume":"10","author":"Barbara","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"key":"B21","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update) \u2013Vaccins contre les papillomavirus humains: note de synth\u00e8se de l\u2019OMS (mise \u00e0 jour de 2022)","volume":"97","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70481-4","article-title":"Present status of human papillomavirus vaccine development and implementation","volume":"16","author":"Herrero","year":"2015","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100177","article-title":"Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis","volume":"8","author":"Brotherton","year":"2019","journal-title":"Papillomavirus Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)30298-3","article-title":"Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis","volume":"394","author":"Drolet","year":"2019","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj.l1161","article-title":"Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: Retrospective population study","volume":"365","author":"Palmer","year":"2019","journal-title":"BMJ"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"pii=1700737","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent","volume":"23","author":"Patel","year":"2018","journal-title":"Euro Surveill."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.065","article-title":"Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs","volume":"40","author":"Markowitz","year":"2022","journal-title":"Vaccine"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1625644","article-title":"A ten-year study of immunogenicity and safety of the AS04-HPV-16\/18 vaccine in adolescent girls aged 10-14 years","volume":"15","author":"Schwarz","year":"2019","journal-title":"Hum Vaccines Immunother"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2023.2209001","article-title":"Safety and immunogenicity of a bivalent HPV16\/18 vaccine in Chinese females","volume":"19","author":"Shi","year":"2023","journal-title":"Hum Vaccines Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.06.028","article-title":"Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis","volume":"35","author":"Bissett","year":"2017","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.01.060","article-title":"Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines","volume":"39","author":"Stanley","year":"2021","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"De Vincenzo","year":"2014","journal-title":"Int J Womens Health"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.076","article-title":"Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence","volume":"39","author":"Brown","year":"2021","journal-title":"Vaccine"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013479","article-title":"Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males","volume":"2019","author":"Bergman","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jog.13634","article-title":"Global human papilloma virus vaccine implementation: An update","volume":"44","author":"Sabeena","year":"2018","journal-title":"J Obstet Gynaecol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.14744\/ejmi.2023.69727","article-title":"Efficacy of the HPV vaccine in the secondary prevention of cervical dysplasia in patients undergoing surgery","volume":"7","author":"Sutcuoglu","year":"2023","journal-title":"EJMI"},{"key":"B39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/aogs.14359","article-title":"Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis","volume":"101","author":"Eriksen","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines10020239","article-title":"HPV Vaccination after Primary Treatment of HPV-Related Disease across Different Organ Sites: A Multidisciplinary Comprehensive Review and Meta-Analysis","volume":"10","author":"Di Donato","year":"2022","journal-title":"Vaccines"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1386167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T13:46:25Z","timestamp":1713879985000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1386167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":40,"alternative-id":["10.3389\/fonc.2024.1386167"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1386167","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"article-number":"1386167"}}